Morgan Stanley Clearside Biomedical, Inc. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Morgan Stanley holds 145,990 shares of CLSD stock, worth $169,348. This represents 0.0% of its overall portfolio holdings.
Number of Shares
145,990
Previous 153,044
4.61%
Holding current value
$169,348
Previous $234,000
19.23%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CLSD
# of Institutions
53Shares Held
13.4MCall Options Held
17.6KPut Options Held
100-
Vanguard Group Inc Valley Forge, PA2.84MShares$3.29 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.55 Million3.43% of portfolio
-
Armistice Capital, LLC New York, NY2.14MShares$2.48 Million0.04% of portfolio
-
Carmignac Gestion Paris, I02.13MShares$2.47 Million0.05% of portfolio
-
Black Rock Inc. New York, NY798KShares$925,8380.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $69.8M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...